Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00113568 · ClinicalTrials.gov registry record · Phase 3
Safety Study of XP12B in Women With Menorrhagia
A Phase 3 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 784
- Enrollment target
NCT00113568 is a Phase 3 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 784 participants.
The verdict
NCT00113568, a Phase 3 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 784 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of XP12B in women with heavy menstrual bleeding associated with menorrhagia.
Interventions
- DRUG Tranexamic acid tablets (XP12B)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 784 participants |
| Start Date | 2005-06 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00113568
The ClinicalTrials.gov registry entry for NCT00113568 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 784 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tranexamic acid tablets (XP12B) is the first listed.
NCT00113568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00113568 about?
NCT00113568 is a clinical study titled "Safety Study of XP12B in Women With Menorrhagia". The purpose of this study is to evaluate the safety of XP12B in women with heavy menstrual bleeding associated with menorrhagia.
What is the current status of trial NCT00113568?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 784 participants. The study started on 2005-06. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00113568?
The interventions under investigation include: Tranexamic acid tablets (XP12B) (DRUG).
Who is sponsoring clinical trial NCT00113568?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.